Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
04/18/19 1:40 PM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Apr 16 2019
Summary ToggleAdverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
- Apr 15 2019
Summary ToggleAdverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
- Apr 1 2019
Summary ToggleAdverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
- Mar 18 2019
Summary ToggleAdverum Biotechnologies to Participate in Upcoming Conferences
There are currently no events to display.